Related Experiment Video

Updated: Dec 28, 2025

Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants
07:38

Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants

Published on: June 6, 2025

564

mTOR Regulation of Metabolism in Hematologic Malignancies

Simone Mirabilii1, Maria Rosaria Ricciardi1, Agostino Tafuri1,2

  • 1Department of Clinical and Molecular Medicine, Sapienza University of Rome, 00185 Rome, Italy.

Cells
|February 15, 2020
PubMed

Insights

Cancer cells alter metabolism for survival and therapy resistance. The mammalian Target of Rapamycin (mTOR) pathway is crucial in hematologic malignancies, offering therapeutic targets by modulating cancer cell metabolism.

Area of Science:

  • Oncology
  • Molecular Biology
  • Cancer Metabolism

Background:

  • Neoplastic cells exhibit altered metabolic pathways conferring survival and therapeutic resistance.
  • The mammalian Target of Rapamycin (mTOR) pathway is a key regulator of cellular metabolism.
  • mTOR is frequently hyperactivated in various hematologic malignancies.

Purpose of the Study:

  • To review the literature on the role of mTOR in metabolic reprogramming in hematologic malignancies.
  • To explore the interplay between mTOR, other metabolic regulators (AMPK, HIF1α), and the tumor microenvironment.
  • To highlight the therapeutic potential of targeting mTOR-driven metabolic alterations.

Main Methods:

  • Literature review and synthesis of existing research.
  • Analysis of studies investigating mTOR signaling in cancer metabolism.
  • Examination of the impact of microenvironmental factors on metabolic phenotypes.

Main Results:

  • mTOR plays a central role in establishing unique metabolic phenotypes in hematologic cancers.
  • Metabolic reprogramming is influenced by interactions between mTOR, AMPK, HIF1α, and microenvironmental stimuli.
  • These mTOR-mediated metabolic adaptations contribute to cancer cell survival and drug resistance.

Conclusions:

  • Targeting the mTOR pathway and its associated metabolic alterations presents a promising therapeutic strategy for hematologic malignancies.
  • Understanding the complex interplay of metabolic regulators is key to developing effective cancer therapies.
  • Modulating cancer cell metabolism via mTOR inhibition can overcome therapeutic resistance.
Keywords:
cell metabolismhematologic malignanciesmTOR

More Related Videos

Analysis of Hematopoietic Stem Progenitor Cell Metabolism12:20

Analysis of Hematopoietic Stem Progenitor Cell Metabolism

Published on: November 9, 2019

7.2K
Assessment of the Metabolic Profile of Primary Leukemia Cells06:21

Assessment of the Metabolic Profile of Primary Leukemia Cells

Published on: November 21, 2018

10.9K

Related Concept Videos

mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
4.5K
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a...
5.1K
Regulation of Metabolism01:19

Regulation of Metabolism

Cellular needs and conditions vary from cell to cell and change within individual cells over time. For example, the required enzymes and energetic demands of stomach cells are different from those of fat storage cells, skin cells, blood cells, and nerve cells. Furthermore, a digestive cell works much harder to process and break down nutrients during the time that closely follows a meal compared with many hours after a meal. As these cellular demands and conditions vary, so do the amounts and...
11.3K
Regulation of Hematopoietic Stem Cells01:01

Regulation of Hematopoietic Stem Cells

All blood and immune cells are produced from the multipotent hematopoietic stem cells (HSCs) by the process of hematopoiesis. However, they all have a limited life span. In addition, many are depleted in immune surveillance or combatting an injury or infection. This makes blood one of the most regenerative tissues. Hematopoiesis helps replenish these blood and immune cells, restoring the body's normal functioning. However, overproduction of blood and immune cells can make them cancerous or...
3.8K
Role of Hematopoietic Growth Factors01:28

Role of Hematopoietic Growth Factors

Hematopoietic growth factors are molecules that regulate the differentiation rate of hematopoietic stem cells (HSCs). Erythropoietin (EPO), primarily produced by the kidneys, plays a crucial role in erythrocyte production. When oxygen levels in the blood are low, EPO is released into the bloodstream, reaching the bone marrow, where it stimulates HSCs to differentiate and mature into erythrocytes, which are vital for oxygen transport.
Thrombopoietin (TPO), mainly released by the liver,...
3.0K
Therapeutic Drug Monitoring: Affecting Factors01:29

Therapeutic Drug Monitoring: Affecting Factors

Therapeutic Drug Monitoring (TDM) is the clinical practice of measuring specific drug levels in a patient's blood or body tissues to manage and optimize therapy. TDM is crucial for drugs with narrow therapeutic windows, like warfarin and phenytoin, where incorrect doses can lead to treatment failure or severe side effects. This monitoring ensures the dosage administered is within a safe and effective range. The factors affecting therapeutic drug monitoring include:Patient-Specific Factors:a.
138